If you have latent tuberculosis, you may need to take only one or two types of TB drug. Active tuberculosis, particularly if it's a drug-resistant strain, will require several drugs at once. The most common medications used to treat tuberculosis include:
Isoniazid
Rifampin (Rifadin, Rimactane)
Ethambutol (Myambutol)
Pyrazinamide

Market Analysis and Insights: Global Tuberculosis (TB) Treatment Market
The global Tuberculosis (TB) Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Tuberculosis (TB) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Tuberculosis (TB) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Tuberculosis (TB) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Tuberculosis (TB) Treatment market.

Global Tuberculosis (TB) Treatment Scope and Market Size
Tuberculosis (TB) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Tuberculosis (TB) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Isoniazid
Rifampin (Rifadin, Rimactane)
Ethambutol (Myambutol)
Pyrazinamide

Segment by Application
Active TB
Latent TB

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Johnson & Johnson
Otsuka Pharmaceutical Co., Ltd
Macleods Pharmaceutical Ltd
Dong-A ST Co., Ltd
Lupin Ltd
Janssen Products, LP
Mylan
Sanofi